Premium
Bisphosphonates for the Hypercalcemia of Malignancy in End‐Stage Renal Disease
Author(s) -
Morton A. Ross
Publication year - 1994
Publication title -
seminars in dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.899
H-Index - 78
eISSN - 1525-139X
pISSN - 0894-0959
DOI - 10.1111/j.1525-139x.1994.tb00938.x
Subject(s) - medicine , malignancy , end stage renal disease , stage (stratigraphy) , dialysis , kidney disease , disease , bone disease , end stage kidney disease , urology , osteoporosis , paleontology , biology
Bisphosphonates appear to be the optimal therapy for the hypercalcemia of malignancy; however, they are contraindicated for patients with end‐stage renal disease (ESRD). I have read that, normally, half of the drug is excreted unchanged by the kidney and half is taken up by bone. It's not apparent why a 50% reduction in dose wouldn't be satisfactory for dialysis patients .